Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Instil Bio Inc (TIL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.990.00%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TIL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS improves toward -$0.17 in 2026-Q3 | A supporting condition in Instil Bio Inc's published investment case. The stated target is EPS >= -$0.17. | Intact | EPS worse than -$0.17 in 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
TIL is a high-risk, loss-making healthcare company, not a proven durable compounder. Its long-term thesis is marked intact, with management reducing losses, but confidence in that view is low.
The evidence does not provide a valuation measure or clear account of what the market already assumes, so whether TIL is cheap or expensive versus peers is unclear. The recent earnings misses and loss-making status are known concerns, while the improved sector backdrop may support expectations for healthcare companies.
Near term, another earnings miss is a meaningful risk, given erratic surprises and the recent misses. Management has reduced operating expenses and improved reported losses, while cash declined from $74.7 million in 2026-Q1 to $69.9 million in 2026-Q2; management says funding the operating plan beyond 2027 remains a priority. The evidence on recent performance is mixed, and it does not establish sustained profitability.
The thesis depends on whether management can keep controlling losses and preserve enough cash to fund the operating plan beyond 2027. A guidance cut or further weakness in jobs data could add pressure, while continued earnings strength and higher guidance from sector bellwethers could support the healthcare backdrop. Acquisition and licensing efforts remain an open question, with no specific deal or milestone disclosed.
Over the next 1 to 3 years, TIL’s long-term thesis rests on continued loss control, cash discipline, and evidence of progress beyond exploration of new pipeline opportunities. Low confidence and elevated near-term earnings risk make the evidence thin. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company aims to reduce its net loss per share to about $10.70 for 2025. |
| Recovered |
| Net loss per share exceeds $10.70 in 2025-FY |
Diluted EPS: $-0.63 per share FY2026-Q2; GAAP. Published target: Net loss per share <= $10.70. Target period is not explicitly aligned with this observation. Aug 13, 2026-0.63 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves to about -$7.0M in 2026-Q1 | Instil Bio is cutting its operating losses from -$30.6M to about -$7.0M in one year. | Intact | Operating income worse than -$7.01M in 2026-Q1 | Operating income: $-5.581M FY2026-Q2; GAAP. Published target: Operating income >= -$7.01M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-5,581,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Research and development expenses were $0.3 million and $0.9 million for the three and six months ended June 30, 2026, respectively, compared to $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively.” “Research and development expenses were $0.7 million for the three months ended March 31, 2026, compared to $5.4 million for the three months ended March 31, 2025.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-8.28 → $-8.28 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-07-25 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-07-26 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-07-27 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-07-28 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-07-29 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-07-30 | Unavailable | Unavailable | — / 0 |
| 2026-07-31 | Unavailable | Unavailable | — / 0 |
| 2026-08-01 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-02 | Unavailable | Unavailable | — / 0 |
| 2026-08-03 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-04 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-05 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-06 | Unavailable | Unavailable | — / 0 |
| 2026-08-08 | Unavailable | Unavailable | — / 0 |
| 2026-08-09 | Unavailable | Unavailable | — / 0 |
| 2026-08-10 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-12 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-13 | Unavailable | Unavailable | — / 0 |
| 2026-08-14 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-15 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-16 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-17 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-18 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-19 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-20 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-21 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-22 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-23 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-24 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-25 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-26 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-27 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-28 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-29 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-30 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-08-31 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-01 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-02 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-03 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-04 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-05 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-06 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-07 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-08 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-09 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-10 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-11 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-12 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-13 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-14 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-15 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-16 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-17 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-18 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-19 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-20 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-21 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-22 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-23 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-24 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-25 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-26 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-27 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-28 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-29 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-09-30 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-01 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-02 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-03 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-04 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-05 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-06 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-07 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-08 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-09 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-10 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-11 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-12 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-13 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-14 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-15 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-16 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-17 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-18 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-19 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-20 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-21 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-22 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-23 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-24 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-25 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-26 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-27 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-28 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-29 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-30 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-10-31 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-11-01 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-11-02 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-11-03 | $-8.28 | $8,195,000 | 1 / 1 |
| 2026-11-04 | $-8.28 | $8,195,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.